Comparison Overview

Novo Nordisk

VS

Lonza

Novo Nordisk

Novo Alle, Bagsværd, undefined, 2880, DK
Last Update: 2025-12-02
Between 800 and 849

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 64,615
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Lonza

Muenchensteinerstr. 38, Basel, undefined, 4002, CH
Last Update: 2025-12-01
Between 800 and 849

At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets. By combining technological insight with world-class manufacturing, scientific expertise and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases. While we work in science, there’s no magic formula to how we do it. Our greatest scientific solution is talented people working together, devising commitment and ideas that help our customers to help people. In exchange, we let our people own their careers. Their ideas, big and small, genuinely improve the world. And that’s the kind of work we want to be part of. Our work makes A Meaningful Difference.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 17,491
Subsidiaries: 4
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/novo-nordisk.jpeg
Novo Nordisk
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/lonza.jpeg
Lonza
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Novo Nordisk
100%
Compliance Rate
0/4 Standards Verified
Lonza
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Novo Nordisk in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Lonza in 2025.

Incident History — Novo Nordisk (X = Date, Y = Severity)

Novo Nordisk cyber incidents detection timeline including parent company and subsidiaries

Incident History — Lonza (X = Date, Y = Severity)

Lonza cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/novo-nordisk.jpeg
Novo Nordisk
Incidents

No Incident

https://images.rankiteo.com/companyimages/lonza.jpeg
Lonza
Incidents

No Incident

FAQ

Novo Nordisk company demonstrates a stronger AI Cybersecurity Score compared to Lonza company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Lonza company has disclosed a higher number of cyber incidents compared to Novo Nordisk company.

In the current year, Lonza company and Novo Nordisk company have not reported any cyber incidents.

Neither Lonza company nor Novo Nordisk company has reported experiencing a ransomware attack publicly.

Neither Lonza company nor Novo Nordisk company has reported experiencing a data breach publicly.

Neither Lonza company nor Novo Nordisk company has reported experiencing targeted cyberattacks publicly.

Neither Novo Nordisk company nor Lonza company has reported experiencing or disclosing vulnerabilities publicly.

Neither Novo Nordisk nor Lonza holds any compliance certifications.

Neither company holds any compliance certifications.

Lonza company has more subsidiaries worldwide compared to Novo Nordisk company.

Novo Nordisk company employs more people globally than Lonza company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Novo Nordisk nor Lonza holds SOC 2 Type 1 certification.

Neither Novo Nordisk nor Lonza holds SOC 2 Type 2 certification.

Neither Novo Nordisk nor Lonza holds ISO 27001 certification.

Neither Novo Nordisk nor Lonza holds PCI DSS certification.

Neither Novo Nordisk nor Lonza holds HIPAA certification.

Neither Novo Nordisk nor Lonza holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Sigstore Timestamp Authority is a service for issuing RFC 3161 timestamps. Prior to 2.0.3, Function api.ParseJSONRequest currently splits (via a call to strings.Split) an optionally-provided OID (which is untrusted data) on periods. Similarly, function api.getContentType splits the Content-Type header (which is also untrusted data) on an application string. As a result, in the face of a malicious request with either an excessively long OID in the payload containing many period characters or a malformed Content-Type header, a call to api.ParseJSONRequest or api.getContentType incurs allocations of O(n) bytes (where n stands for the length of the function's argument). This vulnerability is fixed in 2.0.3.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
Description

Monkeytype is a minimalistic and customizable typing test. In 25.49.0 and earlier, there is improper handling of user input which allows an attacker to execute malicious javascript on anyone viewing a malicious quote submission. quote.text and quote.source are user input, and they're inserted straight into the DOM. If they contain HTML tags, they will be rendered (after some escaping using quotes and textarea tags).

Risk Information
cvss4
Base: 7.1
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

SysReptor is a fully customizable pentest reporting platform. Prior to 2025.102, there is a Stored Cross-Site Scripting (XSS) vulnerability allows authenticated users to execute malicious JavaScript in the context of other logged-in users by uploading malicious JavaScript files in the web UI. This vulnerability is fixed in 2025.102.

Risk Information
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:N
Description

Taiko Alethia is an Ethereum-equivalent, permissionless, based rollup designed to scale Ethereum without compromising its fundamental properties. In 2.3.1 and earlier, TaikoInbox._verifyBatches (packages/protocol/contracts/layer1/based/TaikoInbox.sol:627-678) advanced the local tid to whatever transition matched the current blockHash before knowing whether that batch would actually be verified. When the loop later broke (e.g., cooldown window not yet passed or transition invalidated), the function still wrote that newer tid into batches[lastVerifiedBatchId].verifiedTransitionId after decrementing batchId. Result: the last verified batch could end up pointing at a transition index from the next batch (often zeroed), corrupting the verified chain pointer.

Risk Information
cvss4
Base: 8.0
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:U/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A flaw has been found in youlaitech youlai-mall 1.0.0/2.0.0. Affected is the function getById/updateAddress/deleteAddress of the file /mall-ums/app-api/v1/addresses/. Executing manipulation can lead to improper control of dynamically-identified variables. The attack can be executed remotely. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 6.5
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
cvss3
Base: 6.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X